Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06840392 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06840392 · ClinicalTrials.gov record · last posted 2026-08-21

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Study acronym: RECHARGE-2
StatusActive, Not Recruiting
PhasePhase 3
Started2025-03-20
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Protocol amendment history 4 changes detected by DataLookout

2026-06-06
Trial status changed: Recruiting → Active, Not Recruiting
2026-06-06
Trial sites reduced: 138 → 131 locations
2026-06-06
Primary completion moved earlier: 2027-10-29 → 2027-06-03
2026-06-06
Completion moved earlier: 2028-02-07 → 2027-10-21
Trial Details
NCT Number NCT06840392
Lead Sponsor Novartis Pharmaceuticals
Conditions Hidradenitis Suppurativa
Enrollment 565 participants
Start Date 2025-03-20
Primary Completion 2027-06-03 (estimated)
Study Completion 2027-10-21 (estimated)
Updated on ClinicalTrials.gov 2026-08-21